TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation

Nagoya University

Overview

Clinical studies have established that implantation of bone marrow mononuclear cells (BM-MNCs) or peripheral blood mononuclear cells (PB-MNCs) into ischaemic limbs increases collateral vessel formation. We, the investigators at Nagoya University, further investigated the efficacy and safety of autologous implantation of BM-MNCs or PB-MNCs in patients with severe ischaemic limbs who have no other alternative therapeutic options. We also examined a potential limiting factor which reduced the efficacy of therapeutic angiogenesis using cell transplantation (TACT).

Study Type

OBSERVATIONAL

Conditions

Buerger Disease Arteriosclerosis Obliterans

Interventions

Autologous Bone Marrow Mononuclear Cell ImplantationPROCEDURE

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who have chronic limb ischemia, including rest pain, non-healing ischemic ulcers, or both, and who are not candidates for nonsurgical or surgical revascularisation. Exclusion Criteria: * Poorly controlled diabetes mellitus (hemoglobin A1c \[HbA1c\] \> 6.5% and proliferative retinopathy) * Evidence of malignant disorder during the past 5 years * Subjects who cannot survive more than 1 year with other complications * Malignant rheumatic arthritis

Locations (1)

Department of Cardiology, Nagoya University Graduate School of Medicine

Nagoya, Japan

RECRUITING

Central Contacts

Murohara Toyoaki

CONTACT

81-52-744-2149 murohara@med.nagoya-u.ac.jp

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.